An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
The purpose of this study is to test the feasibility and tolerability of donepezil in a small group of patients with anorexia nervosa (AN). Study participants will be receiving care at the New York State Psychiatric Institute Eating Disorders Unit. Study medication will be increased from 1 mg per day to a maximum of 5 mg per day for up to 8 weeks. Participants will be closely monitored for side effects by a research psychiatrist every week, in addition to the regular clinical monitoring they receive during inpatient treatment. The study will also include assessments of habit strength to measure any changes in maladaptive eating habits over the course of the treatment.
Indication: Anorexia Nervosa
Modality: small molecule
Target: Donepezil
Sponsor: New York State Psychiatric Institute
Source URL: ClinicalTrials.gov
Source updated: Jul 14, 2025
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Donepezil
View original source fields
Condition raw: Anorexia Nervosa
Condition normalized: Anorexia Nervosa
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Donepezil
Target normalized: Donepezil